| Bioactivity | RXPA 380 is a C-terminal specific angiotensin-converting enzyme (ACE) inhibitor with a Ki of 3 nM. RXPA 380 inhibits C-domain mutants of human recombinant ACE with an IC50 of 2.5 nM[1]. |
| Target | Ki: 3 nM (C-terminal ACE), 10 μM (N-terminal ACE)IC50: 2.5 nM (C-domain mutants of human recombinant ACE), 10 μM (N-domain mutants of human recombinant ACE) |
| Invitro | RXPA 380 shows Ki(app) values of 12 nM and 12 μM for the C- and N-domain of mouse somatic ACE[1]. |
| In Vivo | RXPA 380 (0.9-30 mg/kg; i.v.; once) inhibits ACE activity in mice[1]. Animal Model: |
| Name | RXPA 380 |
| CAS | 564479-79-4 |
| Formula | C33H36N3O7P |
| Molar Mass | 617.63 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Georgiadis D, et al. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. Circ Res. 2003 Jul 25;93(2):148-54. |
RXPA 380
CAS: 564479-79-4 F: C33H36N3O7P W: 617.63
RXPA 380 is a C-terminal specific angiotensin-converting enzyme (ACE) inhibitor with a Ki of 3 nM. RXPA 380 inhibits C-d
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.